Antibiotic-resistant MRSA infections are a growing problem. I really wish more people knew about phage therapy. A multi-phage treatment for serious Staphylococcus aureus infections just got FDA Breakthrough status & is moving to Phase 3.
Armata Pharmaceuticals' Phage Therapy for MRSA Infections Receives FDA Breakthrough Designation and
Armata Pharmaceuticals has received FDA Breakthrough Therapy designation for AP-SA02, an intravenous multi-phage therapy designed to combat complicated Staphylococcus aureus bacteremia, including anti
vertexaisearch.cloud.google.com
September 24, 2026 at 8:02 AM
Antibiotic-resistant MRSA infections are a growing problem. I really wish more people knew about phage therapy. A multi-phage treatment for serious Staphylococcus aureus infections just got FDA Breakthrough status & is moving to Phase 3.
Could this be a breakthrough in ID?
Top-line results from diSArm, the first Phase 1b/2a RCT of IV phage therapy (Armata’s AP-SA02) in SA bacteremia showed 88% clinical response at day 12 TOCD12(vs 58% BAT,p=0.047) & 100% response at EOS (vs 25% BAT) #idsky
www.stocktitan.net/news/ARMP/ar...
Top-line results from diSArm, the first Phase 1b/2a RCT of IV phage therapy (Armata’s AP-SA02) in SA bacteremia showed 88% clinical response at day 12 TOCD12(vs 58% BAT,p=0.047) & 100% response at EOS (vs 25% BAT) #idsky
www.stocktitan.net/news/ARMP/ar...
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met. AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best...
www.stocktitan.net
May 21, 2025 at 9:06 PM
Could this be a breakthrough in ID?
Top-line results from diSArm, the first Phase 1b/2a RCT of IV phage therapy (Armata’s AP-SA02) in SA bacteremia showed 88% clinical response at day 12 TOCD12(vs 58% BAT,p=0.047) & 100% response at EOS (vs 25% BAT) #idsky
www.stocktitan.net/news/ARMP/ar...
Top-line results from diSArm, the first Phase 1b/2a RCT of IV phage therapy (Armata’s AP-SA02) in SA bacteremia showed 88% clinical response at day 12 TOCD12(vs 58% BAT,p=0.047) & 100% response at EOS (vs 25% BAT) #idsky
www.stocktitan.net/news/ARMP/ar...
Die erste Phagentherapie der Welt gegen den Krankenhauskeim MRSA geht in die entscheidende Zulassungsstufe. Seit 100 Jahren warten Forscher auf diesen Moment.
Erste Phagentherapie gegen MRSA erreicht Phase 3
Armata Pharmaceuticals hat im Januar 2026 angekündigt, seinen Phagentherapie-Kandidaten AP-SA02 in Phase 3 zu führen. Es ist das erste Mal weltweit, dass eine Phagentherapie diese Stufe klinischer Forschung erreicht. Ziel ist eine Behandlung für gefä
denkstrom.org
May 31, 2026 at 6:17 PM
Die erste Phagentherapie der Welt gegen den Krankenhauskeim MRSA geht in die entscheidende Zulassungsstufe. Seit 100 Jahren warten Forscher auf diesen Moment.
this armata pharma news is pretty wild. they're pushing a bacteriophage therapy (viruses that target bacteria) into phase 3 for tough mrsa bloodstream infections by 2026. a superiority study, no less. didn't expect to see phages this far along so soon.
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activitie
Armata Pharmaceuticals is advancing a novel bacteriophage therapeutic, AP-SA02, towards a Phase 3 clinical trial to treat severe antibiotic-resistant bacterial infections. This investigational therapy
www.prnewswire.com
July 20, 2026 at 8:05 PM
this armata pharma news is pretty wild. they're pushing a bacteriophage therapy (viruses that target bacteria) into phase 3 for tough mrsa bloodstream infections by 2026. a superiority study, no less. didn't expect to see phages this far along so soon.
Armata Pharmaceuticals Receives FDA Agreement for Pediatric Study of AP-SA02 Targeting Staphylococcus aureus Bacteremia#USA#Los_Angeles#Armata_Pharmaceuticals#AP-SA02#Staphylococcus_aureus
Armata Pharmaceuticals Receives FDA Agreement for Pediatric Study of AP-SA02 Targeting Staphylococcus aureus Bacteremia
Armata Pharmaceuticals has achieved a significant regulatory milestone with FDA approval of a pediatric study plan for AP-SA02 to treat complicated Staphylococcus aureus bacteremia in children.
third-news.com
July 13, 2026 at 11:13 AM
Armata Pharmaceuticals Receives FDA Agreement for Pediatric Study of AP-SA02 Targeting Staphylococcus aureus Bacteremia#USA#Los_Angeles#Armata_Pharmaceuticals#AP-SA02#Staphylococcus_aureus
Die erste Phagentherapie der Welt gegen den Krankenhauskeim MRSA geht in die entscheidende Zulassungsstufe. Seit 100 Jahren warten Forscher auf diesen Moment.
Erste Phagentherapie gegen MRSA erreicht Phase 3
Armata Pharmaceuticals hat im Januar 2026 angekündigt, seinen Phagentherapie-Kandidaten AP-SA02 in Phase 3 zu führen. Es ist das erste Mal weltweit, dass eine Phagentherapie diese Stufe klinischer Forschung erreicht. Ziel ist eine Behandlung für gefä
denkstrom.org
August 4, 2026 at 3:32 AM
Die erste Phagentherapie der Welt gegen den Krankenhauskeim MRSA geht in die entscheidende Zulassungsstufe. Seit 100 Jahren warten Forscher auf diesen Moment.
Don't miss Dr. John Williamson at #IDWeek2025 as he shares updates on a Phase 2a clinical trial for complicated S. aureus bacteremia. He'll detail efficacy and safety results of bacteriophage cocktail (AP-SA02) vs placebo along with standard antibiotic therapy. One to watch!
October 22, 2025 at 1:02 PM
Don't miss Dr. John Williamson at #IDWeek2025 as he shares updates on a Phase 2a clinical trial for complicated S. aureus bacteremia. He'll detail efficacy and safety results of bacteriophage cocktail (AP-SA02) vs placebo along with standard antibiotic therapy. One to watch!
Armata Pharmaceuticals (#$ARMP) receives an additional $3.7M in non-dilutive Department of War funding for AP-SA02's Phase 3 program, bringing cumulative support to ~$32.4M. Phase 3 superiority study for complicated S. aureus bacteremia targeted H2 2026.
prismmarketview.com/armata-pharm...
prismmarketview.com/armata-pharm...
Armata Pharmaceuticals Receives $3.7 Million in U.S. Department of War Funding for AP-SA02 Phase 3 Study
Key Points Armata Pharmaceuticals received an additional $3.7 million in non-dilutive funding from the U.S. Department of War for its AP-SA02 Phase 3 clini
prismmarketview.com
September 23, 2026 at 3:38 PM
Armata Pharmaceuticals (#$ARMP) receives an additional $3.7M in non-dilutive Department of War funding for AP-SA02's Phase 3 program, bringing cumulative support to ~$32.4M. Phase 3 superiority study for complicated S. aureus bacteremia targeted H2 2026.
prismmarketview.com/armata-pharm...
prismmarketview.com/armata-pharm...
Armata Pharmaceuticals Secures $3.7 Million for Phase 3 Development of Antibiotic-Resistant Therapy#USA#Los_Angeles#Armata_Pharmaceuticals#AP-SA02#antimicrobial_therapy
Armata Pharmaceuticals Secures $3.7 Million for Phase 3 Development of Antibiotic-Resistant Therapy
Armata Pharmaceuticals has announced the acquisition of an additional $3.7 million in funding from the U.S. Department of War for its Phase 3 development of AP-SA02, targeting antibiotic-resistant infections.
third-news.com
September 23, 2026 at 11:12 AM
Armata Pharmaceuticals Secures $3.7 Million for Phase 3 Development of Antibiotic-Resistant Therapy#USA#Los_Angeles#Armata_Pharmaceuticals#AP-SA02#antimicrobial_therapy
“the responder rate was 100% on AP-SA02 compared to 75% in the control group” www.fiercebiotech.com/biotech/arma...
Armata links bacteria-killing virus to clinical responses in phase 2 trial
Armata Pharmaceuticals has
www.fiercebiotech.com
May 19, 2025 at 4:14 PM
“the responder rate was 100% on AP-SA02 compared to 75% in the control group” www.fiercebiotech.com/biotech/arma...
$ARMP Armata Pharmaceuticals shares are trading after the comapny announced topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous administered multi-phage therapeutic for the treatment of Staphylococcus aureus bacteremia, in the intent-to-treat population.
May 19, 2025 at 4:55 PM
$ARMP Armata Pharmaceuticals shares are trading after the comapny announced topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous administered multi-phage therapeutic for the treatment of Staphylococcus aureus bacteremia, in the intent-to-treat population.
Armata Pharmaceuticals to Share Insights on Genetic Diversity of AP-SA02 at ISSSI 2026#United_States#Los_Angeles#Armata_Pharmaceuticals#AP-SA02#Staphylococcus_aureus
Armata Pharmaceuticals to Share Insights on Genetic Diversity of AP-SA02 at ISSSI 2026
Armata Pharmaceuticals is set to unveil findings at ISSSI 2026 that reveal how genetic diversity in AP-SA02 improves its effectiveness against Staphylococcus aureus.
third-news.com
September 21, 2026 at 11:15 AM
Armata Pharmaceuticals to Share Insights on Genetic Diversity of AP-SA02 at ISSSI 2026#United_States#Los_Angeles#Armata_Pharmaceuticals#AP-SA02#Staphylococcus_aureus
🚨 $ARMP
On September 23, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intra...
On September 23, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intra...
SEC Filing: ARMP
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 11:11 AM
🚨 $ARMP
On September 23, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intra...
On September 23, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intra...
Armata Pharmaceuticals (#$ARMP) presents data at ISSSI 2026 showing AP-SA02's controlled genetic diversity may improve activity against certain S. aureus strains. Preclinical findings; Phase 3 targeted for H2 2026.
prismmarketview.com/armatas-ap-s...
prismmarketview.com/armatas-ap-s...
September 21, 2026 at 3:08 PM
Armata Pharmaceuticals (#$ARMP) presents data at ISSSI 2026 showing AP-SA02's controlled genetic diversity may improve activity against certain S. aureus strains. Preclinical findings; Phase 3 targeted for H2 2026.
prismmarketview.com/armatas-ap-s...
prismmarketview.com/armatas-ap-s...
Armata Pharmaceuticals Achieves FDA Breakthrough Therapy Designation for Innovative AP-SA02 Treatment#United_States#Los_Angeles#Armata_Pharmaceuticals#FDA_Breakthrough#AP-SA02
Armata Pharmaceuticals Achieves FDA Breakthrough Therapy Designation for Innovative AP-SA02 Treatment
Armata Pharmaceuticals celebrates a significant milestone with the FDA granting Breakthrough Therapy designation to AP-SA02, revolutionizing bacterial infection treatment.
third-news.com
September 14, 2026 at 11:06 AM
Armata Pharmaceuticals Achieves FDA Breakthrough Therapy Designation for Innovative AP-SA02 Treatment#United_States#Los_Angeles#Armata_Pharmaceuticals#FDA_Breakthrough#AP-SA02
FDA awards Breakthrough Therapy designation to #$ARMP AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA. notreload.xyz/xy/fda-break...
FDA Breakthrough for Armata’s AP-SA02 Phage Therapy
FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.
notreload.xyz
September 14, 2026 at 12:37 PM
FDA awards Breakthrough Therapy designation to #$ARMP AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA. notreload.xyz/xy/fda-break...
#ARMP Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-fk6gc9x3mwt1.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-fk6gc9x3mwt1.html?utm_source=stocktitan-bluesky&utm_medium=social
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 14, 2026 at 11:00 AM
#ARMP Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-fk6gc9x3mwt1.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-fk6gc9x3mwt1.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $ARMP
On September 14, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for the a...
On September 14, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for the a...
SEC Filing: ARMP
Click to view the official SEC document.
www.sec.gov
September 14, 2026 at 11:13 AM
🚨 $ARMP
On September 14, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for the a...
On September 14, 2026, Armata Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus multi-phage product candidate, for the a...
Armata Pharmaceuticals Reports Second Quarter 2026 Financial Highlights and Corporate Progress#USA#Los_Angeles#Armata_Pharmaceuticals#Bacteriophage_Therapy#AP-SA02
Armata Pharmaceuticals Reports Second Quarter 2026 Financial Highlights and Corporate Progress
Armata Pharmaceuticals has revealed its second quarter 2026 financial performance and pivotal corporate developments, signaling significant advancement in bacterial infection treatment.
third-news.com
August 12, 2026 at 8:21 PM
Armata Pharmaceuticals Reports Second Quarter 2026 Financial Highlights and Corporate Progress#USA#Los_Angeles#Armata_Pharmaceuticals#Bacteriophage_Therapy#AP-SA02
#ARMP Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-announces-financial-results-for-the-second-no0ut255uvnt.html
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-announces-financial-results-for-the-second-no0ut255uvnt.html
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Armata Pharmaceuticals (NYSE American: ARMP) reported second quarter 2026 results and detailed progress on its lead phage therapeutic AP-SA02 for complicated Staphylococcus aureus bacteremia. The company submitted a finalized Phase 3 superiority trial protocol to the FDA, completed key manufacturing assays and engineering runs, and obtained FDA Fast Track designation plus an Agreed Initial Pediatric Study Plan. Armata received an additional $2.5 million in non-dilutive funding from the U.S. Department of War, bringing that award’s total to $28.7 million. For Q2 2026, grant and award revenue was $2.5 million, operating loss was $10.3 million, and net income was $74.1 million driven by a $91.0 million non-cash gain on its Convertible Loan. Cash and cash equivalents rose to $24.0 million at June 30, 2026, following a $25.0 million term loan and at-the-market equity issuance.
www.stocktitan.net
August 12, 2026 at 8:05 PM
#ARMP Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-announces-financial-results-for-the-second-no0ut255uvnt.html
https://www.stocktitan.net/news/ARMP/armata-pharmaceuticals-announces-financial-results-for-the-second-no0ut255uvnt.html
Phage therapy goes mainstream? Quick take: Armata’s AP‑SA02 Phase 3 filing tests bacteriophage adjuncts with antibiotics for Staphylococcus aureus bacteremia—registrational superiority trial ahead. Full breakdown → https://future.xsbrt.com/PhageAdjunctFuture Save or reply.
July 20, 2026 at 11:03 PM
Phage therapy goes mainstream? Quick take: Armata’s AP‑SA02 Phase 3 filing tests bacteriophage adjuncts with antibiotics for Staphylococcus aureus bacteremia—registrational superiority trial ahead. Full breakdown → https://future.xsbrt.com/PhageAdjunctFuture Save or reply.
#$ARMP reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding. notreload.xyz/xy/armata-ar...
Armata (ARMP) Advances AP-SA02 to Phase 3 Trial in 2026
Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.
notreload.xyz
July 20, 2026 at 3:35 PM
#$ARMP reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding. notreload.xyz/xy/armata-ar...
Armata Pharmaceuticals ( #$ARMP) has advanced AP‑SA02, its bacteriophage therapy for complicated Staph bacteremia, toward a planned Phase 3 trial with progress across clinical and manufacturing fronts.
#ARMP #APSA02 #bacteriophage #infectiousdisease #biotech
prismmarketview.com/armata-sets-...
#ARMP #APSA02 #bacteriophage #infectiousdisease #biotech
prismmarketview.com/armata-sets-...
Armata Sets AP‑SA02 Up for Phase 3 in the Fight Against Staph Bacteremia
Armata Pharmaceuticals (NYSE: ARMP) is lining up its lead bacteriophage candidate AP‑SA02 for a pivotal Phase 3 trial, after checking off a series of clinical
prismmarketview.com
July 20, 2026 at 3:33 PM
Armata Pharmaceuticals ( #$ARMP) has advanced AP‑SA02, its bacteriophage therapy for complicated Staph bacteremia, toward a planned Phase 3 trial with progress across clinical and manufacturing fronts.
#ARMP #APSA02 #bacteriophage #infectiousdisease #biotech
prismmarketview.com/armata-sets-...
#ARMP #APSA02 #bacteriophage #infectiousdisease #biotech
prismmarketview.com/armata-sets-...